Market Access for Targeted Therapy in NSCLC
Overview
A pharmaceutical company with a targeted therapy for non-small cell lung cancer (NSCLC) was facing competitive pressures from market-leading alternatives. Despite strong clinical data, the company was losing patients to competitor therapies at key decision points along the patient journey. To refine its commercial strategy, the company needed real-world data (RWD) to analyze
Where and when patients were being prescribed competitor therapies.
Gaps in biomarker testing rates that may be limiting therapy uptake.
Referral and prescribing trends to optimize commercial strategy and physician engagement.
Challenges
Limited visibility into patient journey: Existing data sources failed to capture real-world biomarker testing rates and prescriber behavior at key decision points.
Fragmented data sources: The company needed a comprehensive view combining EHR, molecular, imaging, and pathology data across multiple health systems.
Need for rapid insights: The company required access to federated queries to inform its commercial strategy ahead of upcoming launches.
Privacy & Compliance Constraints: Ensuring HIPAA-compliant access to de-identified patient-level data was a key priority.
Why They Chose datma
The pharma company selected datma for its advanced patient journey mapping capabilities, which provided a comprehensive, real-world view of how NSCLC patients moved through the diagnosis to treatment outcomes. datma.FED enabled access to structured and unstructured health system and lab data, integrating clinical notes, medication records, molecular testing results, and treatment decisions in a privacy-preserving manner. This allowed the company to uncover prescribing patterns, referral trends, and competitive leakage points- all without requiring raw data transfers.
Solution: datma.FED
datma.FED enabled the pharmaceutical company to conduct a comprehensive patient journey analysis by integrating de-identified health system and lab data in a federated model. This approach provided deep insights without requiring direct data transfer.
Identification of leakage points- The company analyzed where eligible patients were being prescribed competitor treatments instead of their targeted therapy.
Multi-site treatment patterns- Access to real-world prescribing behaviors across multiple health systems and labs allowed for optimization of physician engagement strategies.
With privacy-preserved, federated insights, the company was able to refine market access and commercial strategies to drive greater adoption of their targeted NSCLC therapy.